Patient population and treatment needs in chronic liver disease and cirrhosis
First written in FY2021-Q2. 7 of 8 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000.」
The patient population for chronic liver disease and cirrhosis, and the treatment need arising from the lack of an established curative treatment other than liver transplantation, have been reaffirmed. - FY2024-Q3RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000. At present, in standard treatment, no therapy other than liver transplantation has been established that can be expected to cure cirrhosis with advanced fibrosis. There are expectations for the development of new drugs to improve liver fibrosis and promote tissue regeneration without relying on transplant medicine.」
The patient population for chronic liver disease and cirrhosis, and the treatment need arising from the lack of an established curative treatment other than liver transplantation, have been reaffirmed. - FY2024-Q1RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000. At present, in standard treatment, no therapy other than liver transplantation has been established that can be expected to cure cirrhosis with advanced fibrosis. There are expectations for the development of new drugs to improve liver fibrosis and promote tissue regeneration without relying on transplant medicine.」
The patient population for chronic liver disease and cirrhosis, and the treatment need arising from the lack of an established curative treatment other than liver transplantation, have been reaffirmed. - FY2023-Q1RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000. At present, in standard treatment, no therapy other than liver transplantation has been established that can be expected to cure cirrhosis with advanced fibrosis. There are expectations for the development of new drugs to improve liver fibrosis and promote tissue regeneration without relying on transplant medicine.」
The patient population for chronic liver disease and cirrhosis, and the treatment need arising from the lack of an established curative treatment other than liver transplantation, have been reaffirmed. - FY2022RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000.」
The patient population for chronic liver disease and cirrhosis, and the treatment need arising from the lack of an established curative treatment other than liver transplantation, have been reaffirmed. - FY2022-Q1RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000. At present, in standard treatment, no therapy other than liver transplantation has been established that can be expected to cure cirrhosis with advanced fibrosis. There are expectations for the development of new drugs to improve liver fibrosis and promote tissue regeneration without relying on transplant medicine.」
The patient population for cirrhosis and the treatment need arising from the lack of an established curative treatment other than liver transplantation have been reaffirmed. - FY2021-Q3RestatedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis in Japan is estimated at 400,000–500,000. At present, in standard treatment, no therapy other than liver transplantation has been established that can be expected to cure cirrhosis with advanced fibrosis. There are expectations for the development of new drugs to improve liver fibrosis and promote tissue regeneration without relying on transplant medicine.」
The patient population for cirrhosis and the treatment need arising from the lack of an established curative treatment other than liver transplantation have been reiterated. - FY2021-Q2First statedAnnual report
「Cirrhosis with advanced fibrosis can cause various problems affecting life expectancy, including impaired liver function, portal hypertension and carcinogenesis. The number of patients with cirrhosis is estimated at 400,000–500,000 in Japan and 20 million worldwide. At present, in standard treatment, no therapy other than liver transplantation has been established that can be expected to cure cirrhosis with advanced fibrosis. There are expectations for the development of new drugs to improve liver fibrosis and promote tissue regeneration without relying on transplant medicine.」
For cirrhosis, estimates of 400,000–500,000 patients in Japan and 20 million worldwide, together with expectations for the development of therapeutic drugs against the backdrop of no established curative treatment other than liver transplantation, have been presented.